Pharmacokinetic and pharmacodynamic studies form an important foundation for drug development by profiling therapeutic agents and their effects across multiple timepoints. Unfortunately, PK/PD protein measurements are often limited by plate or bead-based methods with narrow dynamic range, relatively large volume requirements, and long assay times. These factors restrict both the quantity and the quality of proteomic data that can be collected from cell-based or animal models. Correlia offers an automated platform to overcome these bottlenecks – enabling highly efficient protein measurements from as little as 2 microliters of a diluted biosample. In this webinar, we focus on case studies in therapeutic antibody development. Both general and specific measurements of monoclonal antibodies are made possible, respectively based upon IgG-generic and ligand-specific binding affinities.
• Protein concentrations can be measured in a fraction of the time and sample volume required for conventional immunoassays.
• Targets are measured in a “sample-in, answer-out” workflow with minimal user intervention.
• Correlia measurements demonstrate extended dynamic range when validated against competing immunoassays.
Samuel Tia, Ph.D.
Chief Science Officer
Samuel Tia is a co-founder and CSO of Correlia Biosystems, where he works with their scientific teams to expand Correlia’s immunoassay test menus and deliver solutions for customer proteomic applications. Dr. Tia received a Ph.D. in Bioengineering from UC Berkeley, where his work in the Herr Lab led to a licensed patent. Prior to graduate studies, he obtained a BS in Mechanical Engineering from the University of Florida and had industry experience in drug delivery and medical-grade manufacturing/packaging.
The information and opinions provided by speakers as well as Sino Biological employees during hosted webinar series are solely of their own and Sino Biological assumes no responsibility or liability for this content.
About Sino Biological
Sino Biological specializes in antibody development and recombinant protein production. All of Sino Biological’s products are independently developed and produced. Sino Biological offers pharmaceutical companies and biotechnology firms a variety of recombinant production and assay services for pre-clinical research development work. Sino Biological is dedicated to virology and infectious disease research. Its ProVir™ collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses. Sino Biological is the first company in the world to produce and supply the SARS-CoV-2 viral protein reagents. To support the development of immunodiagnostic assay, Sino Biological has developed a comprehensive collection of antigens and antibodies for SARS-CoV-2.